Controlling DNA-end resection: a new task for CDKs

DNA double-strand breaks (DSBs) are repaired by two major pathways: homologous recombination (HR) and non-homologous end-joining (NHEJ). The choice between HR and NHEJ is highly regulated during the cell cycle. DNA-end resection, an evolutionarily conserved process that generates long stretches of s...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in genetics Vol. 4; p. 99
Main Authors Ferretti, Lorenza P., Lafranchi, Lorenzo, Sartori, Alessandro A.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:DNA double-strand breaks (DSBs) are repaired by two major pathways: homologous recombination (HR) and non-homologous end-joining (NHEJ). The choice between HR and NHEJ is highly regulated during the cell cycle. DNA-end resection, an evolutionarily conserved process that generates long stretches of single-stranded DNA, plays a critical role in pathway choice, as it commits cells to HR, while, at the same time, suppressing NHEJ. As erroneous DSB repair is a major source of genomic instability-driven tumorigenesis, DNA-end resection factors, and in particular their regulation by post-translational modifications, have become the subject of extensive research over the past few years. Recent work has implicated phosphorylation at S/T-P motifs by cyclin-dependent kinases (CDKs) as a major regulatory mechanism of DSB repair. Intriguingly, CDK activity was found to be critically important for the coordinated and timely execution of DNA-end resection, and key players in this process were subsequently identified as CDK substrates. In this mini review, we provide an overview of the current understanding of how the DNA-end resection machinery in yeast and human cells is controlled by CDK-mediated phosphorylation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Travis H. Stracker, Institute for Research in Biomedicine, Spain; Boris Pfander, Max-Planck Society, Germany
These authors have contributed equally to this work.
Edited by: Antonio Porro, Ecole Polytechnique Federale de Lausanne, Switzerland
This article was submitted to Frontiers in Cancer Genetics, a specialty of Frontiers in Genetics.
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2013.00099